Customer Center
Login | Register

Investor Relations

  • Banner Image

News Releases

Date Title  
Toggle Summary Luminex Receives FDA Emergency Use Authorization for ARIES® SARS-CoV-2 Assay to Detect Virus Responsible for COVID-19 Disease
Luminex is now able to provide SARS-CoV-2 diagnostic tests for both high-complexity, high-throughput reference labs and moderate complexity, sample-to-answer testing facilities AUSTIN, Texas , April 6, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug
Toggle Summary Luminex Receives BARDA Contract to Support Development of Second, Rapid SARS-CoV-2 Test
- Follows BARDA Contract and EUA for NxTAG® CoV Extended Panel last week - ARIES® SARS-CoV-2 Assay will be submitted for EUA later this week AUSTIN, Texas , March 31, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received $642,450 in funding from the Biomedical
Toggle Summary Luminex Receives FDA Emergency Use Authorization for NxTAG® CoV Extended Panel to Detect the SARS-CoV-2 Virus that Causes COVID-19 Disease
BARDA award for $642K helped Luminex accelerate development and validation AUSTIN, Texas , March 27, 2020 /PRNewswire/ --  Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its NxTAG ®  CoV Extended
Toggle Summary Luminex Provides Update on SARS-CoV-2 Validation Testing Efforts
-Four independent clinical laboratories report data from evaluation of automated, sample-to-answer ARIES® System for rapid detection of SARS-CoV-2 virus -Luminex has launched and begun shipping its Research Use Only (RUO) NxTAG® CoV Extended Panel -Luminex is planning to submit an EUA (Emergency
Toggle Summary Luminex Provides Updates on Critical Efforts Related to Novel Coronavirus
Company takes action to help address COVID-19 AUSTIN, Texas , March 4, 2020 /PRNewswire/ -- As the rapidly changing situation associated with the Wuhan coronavirus, now known as SARS-CoV-2, continues to evolve both in the United States and around the world, Luminex Corporation (NASDAQ:LMNX)
Toggle Summary Luminex Corporation Submits VERIGENE® II Respiratory Flex Assay for FDA Clearance
AUSTIN, Texas , Feb. 24, 2020 /PRNewswire/ --  Luminex Corporation  (NASDAQ: LMNX) today announced that the company has submitted an application to the U.S. Food and Drug Administration (FDA) for 510(k) clearance of the VERIGENE ® II Respiratory Flex Assay, the second VERIGENE II assay to be
Toggle Summary Luminex Corporation Declares First Quarter Cash Dividend
AUSTIN, Texas , Feb. 18, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the first quarter of 2020 of $0.09 per share of common stock payable on April 9 , 2020 to stockholders of record as of the close
Toggle Summary Luminex Corporation to Participate At Upcoming Healthcare Investor Conferences in March 2020
AUSTIN, Texas , Feb. 13, 2020 /PRNewswire/ --  Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir , President & CEO, and Harriss Currie , Senior Vice President of Finance and CFO, plan to participate at three investor conferences in March 2020 .
Toggle Summary Luminex Corporation Reports Fourth Quarter and Full-Year 2019 Results
New Products and Effective Execution Support Return To Accelerated Organic Growth AUSTIN, Texas , Feb. 10, 2020 /PRNewswire/ --  Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2019 . All amounts in this release are in conformity
Toggle Summary Luminex Corporation To Release Fourth Quarter and Full-Year 2019 Results After Market Close On February 10, 2020
AUSTIN, Texas , Jan. 23, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the fourth quarter and full-year ended December 31, 2019 on Monday, February 10, 2020 after the market close. The company will host a conference call that day at 5:00